|
Peter Heinrich Krammer (born in 1946) is a German immunologist and one of the directors of The National Center for Tumor Diseases (NCT),〔()〕 as well as the head of the Division Immunogenetics 〔()〕 at the German Cancer Research Center (DKFZ) in Heidelberg. Peter H. Krammer is well known for his research and findings in apoptosis. He and his lab members discovered the CD95 receptor (also known as Fas and APO-1)〔()〕 and many other molecules involved in signaling through the CD95 receptor. == Life == Krammer studied medicine at the University of Freiburg (Germany), in St.Louis (USA) and in Lausanne (Switzerland) and graduated in 1971. He was a member of the Basel Institute for Immunology in Switzerland between 1973 and 1975, and a member of Max Planck Institute for Immunobiology in Freiburg, Germany in 1976. In 1976, he became an associate at the Institute for Immunology and Genetics at the German Cancer Research Center in Heidelberg. Between 1981 and 1988, he was the acting head and since 1989, he is the head of the Division of Immunogenetics at the German Cancer Research Center. In 2000, he was one of the founders of Apogenix,〔()〕 a spin-out from the German Cancer Research Center which is a clinical stage biopharmaceutical company developing novel therapeutics by targeting the modulation of apoptosis. Since 2010, he is also one of the directors of The National Center for Tumor Diseases (NCT). Peter H. Krammer has more than 400 scientific publications.〔()〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Peter H. Krammer」の詳細全文を読む スポンサード リンク
|